2024 annual financial data

Lyell Immunopharma 2024 Financial results

Direct answer

Revenue was 61,000 USD.

Operating income was -358.76M USD and net income was -342.99M USD.
Operating cash flow was -162.39M USD.

Get free Lyell Immunopharma email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Revenue
61,000 USD
Operating income
-358.76M USD
Net income
-342.99M USD
Operating cash flow
-162.39M USD